Dx Deals: Labcorp Acquires Stake in European Testing Giant
$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays
Congress fails to include SALSA in the omnibus federal government spending bill passed at the end of 2022, but delays PAMA price cuts once again.
A decline in COVID-19 testing demand, along with a challenging economy, made for a difficult quarter for diagnostics companies.
Having twice failed to disrupt health care, Amazon opts for a different strategy this time around—and it may just work.
A high volume of FDA approvals for new tests and diagnostic products made up for the relatively low number of approvals in the EU.
Automating travel and expense significantly improves performance, but adding mobility takes such improvements to a much higher level.
The recent FDA approval of an OTC test shows that COVID-19 saliva testing may be poised for bigger and better things in the years ahead.
Though only seven transactions were announced or closed in November, two were billion-dollar deals.
Solutions you can implement right away to address current lab staffing concerns and prepare for the future.
Increasing incidences of heart disease, as well as technological advances, will drive growth over the next eight to 10 years, reports say.
According to a recent report, digital health companies are on track to rake in $21 billion for 2022, below the 2021 total of $29.1 billion.